Internal and emergency medicineJul 7, 2026

GLP-1 Receptor Agonists in Preventing and Treating Cancers Linked to Obesity

GLP-1 Therapies Weekly Brief ↗PubMed ↗DOI ↗OA ↗

Updated Jul 8, 2026

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may offer protective effects against several cancers, including prostate and breast cancer.

GLP-1 RAs can improve glycemic control and promote weight loss in type 2 diabetes and obesity.
Emerging evidence suggests GLP-1 RAs may influence biological pathways related to tumor growth, such as insulin signaling and inflammation.
Observational studies indicate potential protective effects of GLP-1 RAs against prostate, breast, pancreatic, gynecological, glioma, and oral squamous cell cancers.
The lack of large-scale randomized controlled trials with cancer-specific endpoints presents a significant limitation to these findings.
While rodent studies have raised concerns about medullary thyroid carcinoma, human data do not support a significant risk.
Common side effects of GLP-1 RAs, like gastrointestinal discomfort, are typically manageable, but rare adverse events require careful monitoring.

Simplified

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have become pivotal in treating type 2 diabetes and obesity due to their ability to improve glycemic control and promote weight loss. Beyond their metabolic benefits, emerging evidence suggests that GLP-1 RAs may exert anticancer effects by modulating critical biological pathways involved in tumorigenesis, including insulin signaling, inflammation, and cellular proliferation. Current evidence derived from observational and secondary analyses suggests potential protective effects of GLP-1 RAs against several cancers-including prostate, breast, pancreatic, gynecological, glioma, and oral squamous cell cancer through both weight-dependent and independent mechanisms, but the absence of large-scale randomized controlled trials (RCTs) with cancer-specific endpoints remains a critical limitation. Moreover, safety concerns remain a major challenge. Although rodent studies raised concerns regarding medullary thyroid carcinoma, human data have not substantiated a significant risk. Similarly, initial signals of pancreatitis and pancreatic cancer risk have been largely attenuated by subsequent rigorous analyses. Common side effects, such as gastrointestinal discomfort, are usually manageable and transient, but rare adverse events warrant vigilance, particularly in vulnerable patient populations. GLP-1 RAs show emerging signals for cancer prevention and treatment, but their therapeutic application in oncology should proceed cautiously. Future research must prioritize well-designed, adequately powered cancer-focused RCTs that evaluate both efficacy and safety over extended periods.

Full Text

Full text is available at the source.

View Full Text ↗

Funding

Competing interests

Declarations. Conflict of interest: The authors declare that there are no conflicts of interest. Informed consent: Not applicable.

PubMed

GLP-1 Receptor Agonists in Preventing and Treating Cancers Linked to Obesity

Abstract

Full Text

Funding

Competing interests

You found one interesting study. We’ll send the next 7.

What Lands in Your Inbox Each Week:

Recent issues from the glp-1 therapies brief